Wanbury Limited Reports 117% PAT Growth in FY26; EPS More Than Doubles to 20.55

Wanbury Limited Reports 117% PAT Growth in FY26; EPS More Than Doubles to 20.55​

Wanbury Limited, a pharmaceutical company with global API presence and a domestic branded formulations portfolio, today announced its audited financial results for the full year and fourth quarter ended March 31, 2026. The company reported a 117% year-on-year increase in Profit After Tax (PAT) to "66.1 Cr.

The financial results highlight strong bottom-line growth, with Earnings Per Share (EPS) more than doubling to "20.55 in FY26. This growth was underpinned by operational efficiencies, favorable product mix, and improvements in procurement processes.

FY26 Financial Performance Highlights​

The company recorded robust performance across major metrics for the full fiscal year:


*EBITDA figures include Other Income.

For the fourth quarter (Q4 FY26), the company reported:

Operational and Business Momentum​

Wanbury Ltd reported significant operational milestones alongside its financial achievements. The company’s API portfolio strength was highlighted by the successful launch of a new Anaesthetic API from its Tanuku facility, with commercial dispatches to Europe beginning in February 2026 following the completion of CAPEX.

The company's API pipeline is set to strengthen with upcoming specialties including Dextromethorphan HBr, Rivaroxaban, and Sitagliptin.

On the regulatory front, the company secured key approvals, including zero observations in the MFDS, Korea inspection conducted between April 7 and April 9, 2026. Furthermore, it achieved zero observation status from the USFDA inspection at the Patalganga facility and zero observations in the ANVISA Brazil inspection. The company also secured ANVISA, Brazil approval for Sertraline Form II, thereby deepening its regulated market access.

Operational improvements were further visible in the formulations business, with the implementation of SAP HANA 54 to drive efficiencies across the organization.

Q4 Context and Management View​

The Q4 FY26 revenue from operations stood at '164.6 Cr, which reflected an impact from a crisis in West Asia in late February, which disrupted API export dispatches during March, affecting the quarterly revenue for this largely export-led business. Despite the revenue impact, the gross margin expanded by 887 bps to 60.4%, supported by better product mix and internal cost efficiency initiatives.

Mr. Mohan Rayana, Director, Wanbury Limited, stated that FY26 was an important year, noting that the company strengthened its fundamentals through operational efficiencies, balance sheet improvement, and expanding its API and formulations portfolio. He pointed out that the launch of the new Anaesthetic API with commercial dispatches in February 2026 was a key milestone. Mr. Rayana added that the zero observations from the MFDS, Korea inspection validated the company’s compliance systems, setting a trajectory for continued API growth in FY27.

WANBURY Stock Price Movement​

As of 12:22 PM, shares of Wanbury Limited are slipping by 2.08% in live trading, currently trading at ₹261. The stock sees considerable activity, having traded 57,735 shares so far today.